About Nivalis
Nivalis is a company based in Boulder (United States) founded in 2007 was acquired by Alpine Immune Sciences in April 2017.. Nivalis has raised $50 million across 5 funding rounds from investors including Alpine Immune Sciences, RA Capital and Jennison Associates. Nivalis operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Boulder, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$50 M (USD)
in 5 rounds
-
Latest Funding Round
$30 M (USD), Series C
Nov 24, 2014
-
Investors
Alpine Immune Sciences
& 8 more
-
Employee Count
Employee Count
-
Acquired by
Alpine Immune Sciences
(Apr 18, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Nivalis
Nivalis has successfully raised a total of $50M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $30.0M
- First Round First Round
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2014 | Amount | Series C - Nivalis | Valuation |
investors |
|
| Nov, 2014 | Amount | Debt – Conventional - Nivalis | Valuation |
investors |
|
| Jul, 2010 | Amount | Series B - Nivalis | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nivalis
Nivalis has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Alpine Immune Sciences, RA Capital and Jennison Associates. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Venture and private equity investments are managed with global diversification.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nivalis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nivalis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nivalis Comparisons
Competitors of Nivalis
Nivalis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for rare genetic diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Nivalis
When was Nivalis founded?
Nivalis was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Where is Nivalis located?
Nivalis is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Is Nivalis a funded company?
Nivalis is a funded company, having raised a total of $50M across 5 funding rounds to date. The company's 1st funding round was a Series B of $10M, raised on Oct 28, 2008.
What does Nivalis do?
Nivalis was founded in 2007 in Boulder, United States, within the biotechnology sector. Small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) are developed by the company for cystic fibrosis treatment. Focus is placed on patients homozygous for the F508del mutation in the CFTR gene. The lead candidate has advanced to phase II clinical trials, addressing clinical needs in this area.
Who are the top competitors of Nivalis?
Nivalis's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
Who are Nivalis's investors?
Nivalis has 9 investors. Key investors include Alpine Immune Sciences, RA Capital, Jennison Associates, Rock Springs Capital, and Deerfield.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.